Stay updated with breaking news from Foundationone Cdx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--May 29, 2024--
Chugai Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Provide Information on Detection of Copy Number Alterations...
/PRNewswire/ -- The "Precision Cancer Diagnostic Test Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering. World revenue for the...
The FDA has approved the FoundationOne® CDx for use as a companion diagnostic to identify patients with advanced hormone receptor–positive, HER2-negative advanced breast cancer who may be eligible for treatment with the combination of capivasertib and fulvestrant.
Truqap (capivasertib) with the chemotherapy fulvestrant has been approved for the treatment of adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, the FDA announced.